Akari Therapeutics (NASDAQ:AKTX) Shares Cross Above 50-Day Moving Average – Time to Sell?

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $8.53 and traded as high as $14.05. Akari Therapeutics shares last traded at $13.17, with a volume of 61,659 shares.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Akari Therapeutics in a report on Monday, April 20th. Maxim Group lowered shares of Akari Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, April 8th. Finally, HC Wainwright increased their price objective on shares of Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a report on Wednesday, April 1st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $89.00.

Akari Therapeutics Price Performance

The company’s fifty day moving average is $8.53 and its 200 day moving average is $9.72.

Akari Therapeutics (NASDAQ:AKTX) last posted its quarterly earnings results on Wednesday, May 20th. The biopharmaceutical company reported ($688.00) EPS for the quarter, missing the consensus estimate of ($1.33) by ($686.67).

Institutional Inflows and Outflows

An institutional investor recently raised its position in Akari Therapeutics stock. Cresset Asset Management LLC boosted its holdings in Akari Therapeutics PLC (NASDAQ:AKTX) by 4,368.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 822,468 shares of the biopharmaceutical company’s stock after buying an additional 804,060 shares during the period. Cresset Asset Management LLC owned approximately 2.52% of Akari Therapeutics worth $831,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.